These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1108 related articles for article (PubMed ID: 25499080)

  • 1. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
    Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
    Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent blockade of NF-κB and Akt pathways potentiates cisplatin's antitumor activity in vivo.
    Sun H; Zheng X; Wang Q; Yan J; Li D; Zhou Y; Lin Y; Zhang L; Wang X
    Anticancer Drugs; 2012 Nov; 23(10):1039-46. PubMed ID: 22760211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NF-κB activity is downregulated by KRAS knockdown in SW620 cells via the RAS-ERK-IκBα pathway.
    Lin G; Tang Z; Ye YB; Chen Q
    Oncol Rep; 2012 May; 27(5):1527-34. PubMed ID: 22327383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo.
    Zhou J; Zheng B; Ji J; Shen F; Min H; Liu B; Wu J; Zhang S
    Tumour Biol; 2015 May; 36(5):3301-8. PubMed ID: 25524577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
    Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
    Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aurora-A promotes gefitinib resistance via a NF-κB signaling pathway in p53 knockdown lung cancer cells.
    Wu CC; Yu CT; Chang GC; Lai JM; Hsu SL
    Biochem Biophys Res Commun; 2011 Feb; 405(2):168-72. PubMed ID: 21216229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The biphasic role of NF-kappaB in progression and chemoresistance of ovarian cancer.
    Yang G; Xiao X; Rosen DG; Cheng X; Wu X; Chang B; Liu G; Xue F; Mercado-Uribe I; Chiao P; Du X; Liu J
    Clin Cancer Res; 2011 Apr; 17(8):2181-94. PubMed ID: 21339307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1α-mediated regulation of apoptosis and autophagy.
    Zhang X; Qi Z; Yin H; Yang G
    Theranostics; 2019; 9(4):1096-1114. PubMed ID: 30867818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IKKβ targeting reduces KRAS-induced lung cancer angiogenesis in vitro and in vivo: A potential anti-angiogenic therapeutic target.
    Carneiro-Lobo TC; Scalabrini LC; Magalhães LDS; Cardeal LB; Rodrigues FS; Dos Santos EO; Baldwin AS; Levantini E; Giordano RJ; Bassères DS
    Lung Cancer; 2019 Apr; 130():169-178. PubMed ID: 30885340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 gene expression and 2-methoxyestradiol treatment differentially induce nuclear factor kappa B activation in human lung cancer cells with different p53 phenotypes.
    Rath PC; Mukhopadhyay T
    DNA Cell Biol; 2009 Dec; 28(12):615-23. PubMed ID: 19715480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells.
    Jiang XH; Wong BC; Lin MC; Zhu GH; Kung HF; Jiang SH; Yang D; Lam SK
    Oncogene; 2001 Nov; 20(55):8009-18. PubMed ID: 11753684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
    Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
    Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis.
    Dong QG; Sclabas GM; Fujioka S; Schmidt C; Peng B; Wu T; Tsao MS; Evans DB; Abbruzzese JL; McDonnell TJ; Chiao PJ
    Oncogene; 2002 Sep; 21(42):6510-9. PubMed ID: 12226754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hexabromocyclododecane and polychlorinated biphenyls increase resistance of hepatocellular carcinoma cells to cisplatin through the phosphatidylinositol 3-kinase/protein kinase B pathway.
    An J; Wang X; Guo P; Zhong Y; Zhang X; Yu Z
    Toxicol Lett; 2014 Aug; 229(1):265-72. PubMed ID: 24960055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-217 functions as a tumour suppressor gene and correlates with cell resistance to cisplatin in lung cancer.
    Guo J; Feng Z; Huang Z; Wang H; Lu W
    Mol Cells; 2014 Sep; 37(9):664-71. PubMed ID: 25234467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
    Kim J; McMillan E; Kim HS; Venkateswaran N; Makkar G; Rodriguez-Canales J; Villalobos P; Neggers JE; Mendiratta S; Wei S; Landesman Y; Senapedis W; Baloglu E; Chow CB; Frink RE; Gao B; Roth M; Minna JD; Daelemans D; Wistuba II; Posner BA; Scaglioni PP; White MA
    Nature; 2016 Oct; 538(7623):114-117. PubMed ID: 27680702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-(4-hydroxyphenyl)retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of I(kappa)B(alpha) kinase and nuclear factor-kappaB-regulated gene products.
    Shishodia S; Gutierrez AM; Lotan R; Aggarwal BB
    Cancer Res; 2005 Oct; 65(20):9555-65. PubMed ID: 16230421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
    J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apoptosis of human fibrosarcoma HT-1080 cells by epigallocatechin-3-O-gallate via induction of p53 and caspases as well as suppression of Bcl-2 and phosphorylated nuclear factor-κB.
    Lee MH; Han DW; Hyon SH; Park JC
    Apoptosis; 2011 Jan; 16(1):75-85. PubMed ID: 20963498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BAY61-3606 potentiates the anti-tumor effects of TRAIL against colon cancer through up-regulating DR4 and down-regulating NF-κB.
    Du J; Wang Y; Chen D; Ji G; Ma Q; Liao S; Zheng Y; Zhang J; Hou Y
    Cancer Lett; 2016 Dec; 383(2):145-153. PubMed ID: 27721019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.